Ampersand Biosciences awarded Development of Monoclonal Antibodies to Chemokines in the Ferret Model of Respiratory Disease

The two-year project, titled Development of monoclonal antibodies to chemokines in the ferret model of respiratory disease, is funded for $600,000. While the work uses a specialized small animal model, its impact is broad. According to Tori Race, PhD., the contract will expand the portfolio of research tools to further support infectious disease research. It also complements Ampersand’s existing product line, which is already in use by scientists worldwide. Contract # 75N93025C00018.

NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
PSC: AN11 – Health R&D Services; Health Care Services; Basic Research